Stroke Journal

JANUARY 30, 2025

Introduction:The majority of patients with cerebral venous thrombosis (CVT) achieve functional independence (modified Rankin Score [mRS] 0-2), although many continue to experience residual symptoms that negatively impact quality of life. Stroke, Volume 56, Issue Suppl_1 , Page AWP143-AWP143, February 1, 2025. vs 53.810.4;

Thrombosis 40

Thrombosis Strokes Stroke Outcomes 40

CardiacWire

JANUARY 24, 2025

By inhibiting Factor XI (an anticoagulation enzyme), drugs like abelacimab potentially prevent thrombosis without increasing spontaneous bleeding risks. Unfortunately, DOACs often cause gastrointestinal bleeding, which prompted the development of new stroke-prevention methods like Factor XI inhibition. year follow-up.

Strokes 59

Strokes Stroke AFIB Thrombosis 59

Circulation

JANUARY 27, 2025

BACKGROUND:In patients with post-thrombotic syndrome, stent recanalization of iliofemoral veins or the inferior vena cava can restore venous patency and improve functional outcomes. The risk of stent thrombosis is particularly increased during the first 6 months after intervention. points (P=0.36), respectively.

Thrombosis 40

Thrombosis Stents Stent Quality of Life 40

Stroke Journal

FEBRUARY 1, 2024

Background:Direct oral anticoagulants (DOACs) are suitable for some patients with cerebral venous thrombosis (CVT). We examined duration of PA prior to DOAC initiation and outcomes in ACTION-CVT, an international retrospective study.Methods:We compared three groups: no lead-in PA, 1-4 days (d) of PA, and 5-21d of PA. 1-4d, 23.8%

Thrombosis 40

Thrombosis Outcomes Hemorrhage Strokes 40

Heart BMJ

APRIL 15, 2024

Outcomes included heart failure (HF), venous thromboembolism (VTE) and arterial thrombosis/thromboembolism (ATE) recorded in four time windows after SARS-CoV-2 infection: 0–30, 31–90, 91–180 and 181–365 days. Conclusions COVID-19 vaccination reduced the risk of post-COVID-19 cardiac and thromboembolic outcomes.

COVID-19 98

COVID-19 Thrombosis Heart Failure Outcomes 98

Frontiers in Cardiovascular Medicine

MARCH 10, 2024

There are conflicting sources regarding the relationship between hyperglycemia and outcomes in STEMI patients. We aimed to compile evidence to assess the association between hyperglycemia and adverse outcomes. Mortality was the most often outcome reported related to hyperglycemia. 3.45) and 4.47 (95% CI: 2.54–7.87),

Myocardial Infarction 59

Myocardial Infarction Cardiogenic Shock Article STEMI 59

Stroke Journal

FEBRUARY 1, 2024

Introduction:Seizures are a common initial manifestation of cerebral venous thrombosis (CVT). The primary outcome was delayed seizure(s), occurring after 7 days from CVT diagnosis. The primary outcome was delayed seizure(s), occurring after 7 days from CVT diagnosis. Variables with P-value < 0.2

Thrombosis 40

Thrombosis Risk Factors Hemorrhage Outcomes 40

Stroke: Vascular and Interventional Neurology

NOVEMBER 9, 2023

IntroductionCerebral sinus venous thrombosis (CSVT) has traditionally been treated medically with systemic anticoagulation. We included studies that reported outcomes following EVT for CSVT. The primary outcome of interest was rate of modified Rankin Scale (mRS) 0‐2.

Thrombosis 40

Thrombosis Outcomes Strokes Stroke 40

DAIC

JUNE 12, 2024

It enrolled 162 subjects at 30 centers with three patient populations – non-thrombotic iliac vein lesion (NIVL), post-thrombotic syndrome (PTS) and acute deep vein thrombosis (aDVT). Ultimately, the new device promises to enable excellent clinical outcomes and drive significant quality of life improvements.” Res Pract Thromb Haemost.

Stents 105

Stents Stent Anatomy Ultrasound 105

Journal of the American Heart Association

FEBRUARY 14, 2025

We compared procedural complications and clinical outcomes among patients <75 years of age (n=99), those 75 to 84 years of age (n=103), and those 85 years of age (n=71). Recent guidelines and trials have expanded the indications for TAVR to include younger patients with structural valve deterioration.

Aortic valve 40

Aortic valve Aortic TAVR Outcomes 40

DAIC

NOVEMBER 8, 2024

Venita Chandra, director of vascular surgery, Stanford University School of Medicine, showed that DA followed by DCB achieved a significantly lower provisional stent rate with comparable safety and efficacy outcomes compared to standard predilatation prior to DCB, making it a viable alternative for treating long and highly calcified lesions.

Stents 52

Stents Stent Angioplasty Peripheral Arterial Disease 52

Frontiers in Cardiovascular Medicine

MAY 29, 2024

This study investigates clinical outcomes, aortic remodeling, and abdominal aortic perfusion patterns after TEVAR with the novel Castor device.MethodsFrom November 2020 to June 2023, 29 patients with TBAD involving the LSA were treated with the Castor single-branched stent graft. Of the 102 abdominal aortic branches, 94.1%

Stents 52

Stents Stent Aortic Outcomes 52

Cardiometabolic Health Congress

JANUARY 16, 2025

Precision Medicine: Personalizing Prevention for Better Outcomes Precision medicine provides tools to customize prevention and treatment plans based on individual risk factors. Precision medicine, primordial prevention, and addressing systemic barriers can improve outcomes and reduce the burden of CVD globally.

Atherosclerosis 59

Atherosclerosis Risk Factors Coronary Artery Disease Cardiovascular Disease 59

Circulation: Cardiovascular Interventions

JANUARY 24, 2024

Principal safety outcomes were independently adjudicated International Society on Thrombosis and Haemostasis major bleeding at 72 hours post-treatment and mortality within 12 months of treatment. However, utilization and safety of such strategies in broader PE populations remain unclear.

Embolism 75

Embolism Thrombolysis Ultrasound Pulmonary 75

Dr. Smith's ECG Blog

NOVEMBER 15, 2023

MINOCA may be due to: coronary spasm, coronary microvascular dysfunction, plaque disruption, spontaneous coronary thrombosis/emboli , and coronary dissection; myocardial disorders, including myocarditis, takotsubo cardiomyopathy, and other cardiomyopathies. This is in spite of the known proclivity of tighter stenoses to thrombose.

Coronary Angiogram 109

Coronary Angiogram Plaque Thrombosis STEMI 109

Frontiers in Cardiovascular Medicine

JUNE 5, 2024

BackgroundBehcet's disease (BD) is a systematic vasculitis that affects vessels with various sizes, presenting as venous thrombosis and arterial pseudoaneurysms.

Embolism 52

Embolism Aortic Thrombosis Stent 52

Journal of Cardiothoracic Surgery

JULY 4, 2024

To compare the treatment outcomes among percutaneous mechanical thrombectomy (PMT) with AngioJet, Catheter-directed thrombolysis (CDT), and a combination of both.

Thrombolysis 40

Thrombolysis Thrombosis Outcomes Research 40

Open Heart

JANUARY 6, 2022

Colchicine, a cheap and widely used anti-inflammatory has shown promise in improving cardiovascular outcomes. Results The use of colchicine in patients who underwent PCI significantly reduced MACE outcomes (risk ratio 0.73 (95% CI 0.61 This has been shown to increase the likelihood of further major adverse cardiovascular events (MACE).

Coronary Artery Disease 52

Coronary Artery Disease Thrombosis Stent Stents 52

Stroke: Vascular and Interventional Neurology

NOVEMBER 9, 2023

This study aims to investigate the incidence, complications, and outcomes of SAH patients who develop HIT.MethodsICD‐9‐CM and ICD‐10‐CM codes were used to query the National Inpatient Sample for patients with SAH between 2010 and 2019. Patients with SAH are an understudied population in terms of assessing incidence and impact of HIT.

Hemorrhage 40

Hemorrhage Aneurysm Outcomes Thrombosis 40

Stroke Journal

FEBRUARY 1, 2024

Von Willebrand factor (VWF) plays a crucial role in hemostasis and thrombosis by promoting platelet adhesion to the subendothelial matrix and factor VIII stabilization. aureusinfected VWF-deficient mice exhibited reduced infarcts and better long-term functional outcomes (P <0.05 aureusor vehicle on days 0, 2, and 5.

Outcomes 40

Outcomes Strokes Stroke Thrombosis 40

Stroke Journal

JANUARY 30, 2025

However, long-term outcomes remain poorly described, and the prognostic significance of the radiographic findings is uncertain.Methods:We extracted demographics and clinical variables for all infants with DMVT at our institution from 2007 to 2023. Stroke, Volume 56, Issue Suppl_1 , Page ATMP85-ATMP85, February 1, 2025.

Thrombosis 40

Thrombosis Hemorrhage Congenital Outcomes 40

DAIC

MARCH 31, 2025

Abelacimab is currently in Phase 3 development with the lead indication for the prevention of stroke and systemic embolism in patients with atrial fibrillation (LILAC-TIMI 76), in addition to two studies in patients with cancer-associated thrombosis (ASTER and MAGNOLIA). Data from these trials are expected in the second half of 2026.

Atrial Fibrillation 52

Atrial Fibrillation BMI General Cardiology Thrombosis 52

Stroke Journal

JANUARY 30, 2025

Migraine with aura(MwA) is associated with an increased risk of stroke and adverse vascular outcomes compared to those with migraine without aura (MwoA). Patients with any adverse vascular outcomes before the index ECG were excluded. The prevalences of all vascular outcomes are summarized in Table 1. p < 001).

Atrial Fibrillation 40

Atrial Fibrillation Outcomes Coronary Artery Disease Myocardial Infarction 40

Stroke Journal

OCTOBER 31, 2024

Thrombosis is the main pathological process of stroke and is therefore an important therapeutic target in stroke prevention. We review the concepts of stroke immunothrombosis and thromboinflammation and the effect of immune cells on vessel recanalization and patient outcome. Stroke, Ahead of Print.

Strokes 40

Strokes Stroke Thrombosis Plaque 40

Stroke Journal

NOVEMBER 27, 2024

BACKGROUND:Lack of a dedicated thrombectomy device for cerebral venous thrombosis hinders the recanalization ability of endovascular treatment (EVT). The primary efficacy outcome was the proportion of immediate complete recanalization during EVT. Stroke, Volume 56, Issue 1 , Page 5-13, January 1, 2025.

Thrombosis 40

Thrombosis Stents Stent Hemorrhage 40

Frontiers in Cardiovascular Medicine

JANUARY 29, 2025

For younger or thrombophilic patients, careful evaluation of the filter's suitability and extended follow-up are crucial to optimize outcomes.

Thrombosis 52

Thrombosis Embolism Stents Stent 52

Frontiers in Cardiovascular Medicine

MARCH 27, 2024

Additionally, acute heart failure (AHF) can occur in up to 40% of cases, and its presence can impact the clinical outcomes of patients with IE. Common embolism sites include the brain, spleen, kidneys, lungs, and intestines. Cardiogenic shock (CGS) is often more likely to occur after AHF has taken place.

Cardiogenic Shock 64

Cardiogenic Shock Embolism Heart Failure Thrombosis 64

DAIC

OCTOBER 16, 2024

Notably, the Supraflex Cruz stent showed a significant reduction in clinically driven target lesion revascularization (TLR) rates and very low rates of stent thrombosis, despite the fact that the enrolled patients were at substantial risk for bleeding and ischemic events. If you enjoy this content, please share it with a colleague

Stents 52

Stents Stent Thrombosis Coronary Artery Disease 52

Stroke Journal

FEBRUARY 1, 2024

In severe OHSS, increases in capillary permeability can result in hemoconcentration and hypercoagulability leading to thrombotic events, including stroke and cerebral venous thrombosis. The low rate of outcome events after OHSS seen in each of our population-level analyses increases the reliability of these study results.

Thrombosis 40

Thrombosis Inpatient Embolism Myocardial Infarction 40

DAIC

FEBRUARY 18, 2025

Previous studies about heart valve disease have focused on procedural or device outcomes, and less on patient-centered and disease-related outcomes that are relevant to patients physical and mental well-being and quality of life. tim.hodson Tue, 02/18/2025 - 16:41 Feb. tim.hodson Tue, 02/18/2025 - 16:41 Feb.

Heart Valves 52

Heart Valves Quality of Life Cardiothoracic Outcomes 52

Journal of Cardiovascular Pharmacology

NOVEMBER 11, 2024

The clinical effect of drug-drug interactions (DDIs) between antiplatelets and antiretrovirals (ART) on bleeding, thrombosis, and other major adverse cardiovascular events (MACE) is unknown. The primary outcome was the incidence of DDI between ART and P2Y12inh at P2Y12inh initiation. Copyright © 2024 Wolters Kluwer Health, Inc.

Thrombosis 40

Thrombosis Outcomes Article 40

Journal of the American Heart Association

JANUARY 10, 2025

Bleeds were adjudicated using International Society on Thrombosis and Haemostasis criteria. Epistaxis events were less severe than nonepistaxis bleeds (International Society on Thrombosis and Haemostasis major: 3.2% Journal of the American Heart Association, Ahead of Print. versus 20.7%; clinically relevant nonmajor: 64.7% P=0.001).

Atrial Fibrillation 40

Atrial Fibrillation Thrombosis Myocardial Infarction Hemorrhage 40

Open Heart

NOVEMBER 28, 2023

Eligible were all aetiological studies evaluating risk of cardiovascular outcomes after exposure to common RTIs within any follow-up duration. to 44.9)) and deep venous thrombosis (7.8 (4.3 Methods MEDLINE and EMBASE were systematically searched up to 4 November 2022. Evidence was pooled using random-effects models if data allowed.

Myocardial Infarction 52

Myocardial Infarction COVID-19 Cardiovascular Disease Thrombosis 52

Journal of Cardiovascular Pharmacology

SEPTEMBER 5, 2024

This review of the evidence for bivalirudin utilization in ECMO suggests favorable outcomes in circuit-related thrombosis, bleeding, and dosing reliability. This review of the evidence for bivalirudin utilization in ECMO suggests favorable outcomes in circuit-related thrombosis, bleeding, and dosing reliability.

Laboratory 40

Laboratory Thrombosis Pharmacology Pulmonary 40

Dr. S. Venkatesan MD

JANUARY 14, 2024

How common is thrombosis in the culprit artery of Wellen syndrome ? However by no means, we can say thrombosis do not occur. Wellens’ syndrome: incidence, characteristics, and long-term clinical outcomes. RCA and LCX Wellens do occur, making this entity’s perceived unique importance less certain 3. Reference 1.

Anatomy 52

Anatomy Angina STEMI Thrombosis 52

Stroke: Vascular and Interventional Neurology

OCTOBER 2, 2023

Safety outcomes included rates of symptomatic intracranial hemorrhage, parenchymal hematoma type 2, petechial hemorrhage, and in‐stent thrombosis. Similarly, the rate of in‐stent thrombosis was not significantly different between the 2 groups (1.8% 4.98];P=0.589), or petechial hemorrhage (OR, 1.11 [95% CI, 0.38–3.28];P=0.836).

Hemorrhage 40

Hemorrhage Thrombosis Stent Stents 40

Circulation

NOVEMBER 11, 2024

However, it subjects patients to lifelong warfarin therapy after MHVR, with the attendant risk of bleeding and thrombosis. The percentage of time in the therapeutic range (TTR) was used as the primary outcome while bleeding, thrombosis, and other events were the secondary outcomes.Results:A total of 721 patients were enrolled.

Heart Valves 40

Heart Valves Embolism Thrombosis Quality of Life 40